Table 1.
Characteristics of patients enrolled in this study (median values of age, body mass index, and percentage of post-menopause patients). Clinical data, such as subtype of breast cancer, grade, median of Ki67, and of tumor dimension and node status, are also described.
| Characteristics | 1st Cohort | 2nd Cohort | ||
|---|---|---|---|---|
| Responders (n = 13) | Non-Responders (n = 17) | Responders (n = 11) | Non-Responders (n = 20) | |
| Age (median + range) | 57 (39–82) | 64 (45–79) | 47.5 (29–67) | 58 (39–71) |
| Body mass index (median + range) | 25.31 (22.04–32.03) | 25.39 (22.07–33.2) | 32.05 (20.51–46.64) | 28.01 (19.36–39.73) |
| Post-menopause | 76.92% | 58.82% | 45.45% | 77.78% |
| ER+ (PR –/+) | 30.77% | 41.18% | 11.12% | 47.37% |
| HER2+ including triple positive breast cancer | 38.46% | 17.64% | 44.44% | 42.10% |
| TNBC | 30.77% | 41.18% | 44.44% | 10.53% |
| Grade | G1—15.38% | G1—0% | G1—25% | G1—17.65% |
| G2—30.77% | G2—47.06% | G2—37.5% | G2—47.06% | |
| G3—53.85% | G3—52.94% | G3—37.5% | G3—35.29% | |
| Ki67 (median + range) | 47.40% (15–97) | 19.15% (2–80) | 40% (10–75) | 40% (5–90) |
| Tumor dimension in mm (median + range) | 38 (19–63) | 25 (10–70) | 29.5 (7–65) | 25 (9–80) |
| Axillary lymph node invasion status | Negative—38.46% | Negative—35.29% | Negative—44.44% | Negative—23.53% |
| Positive—61.54% | Positive—64.71% | Positive—55.56% | Positive—76.47% | |